Diagnosing and Treating Early Neurotrophic Keratitis (CME Webcast)
Activity Description
Neurotrophic keratitis (NK) is a rare disease with serious consequences to a patient’s vision. It can be less challenging to recognize the tell-tale clinical signs of advanced stages of NK, making early cases of NK easier to overlook in today’s busy practices. Signs and symptoms of early stages of NK can overlap with those of more commonly seen ocular surface diseases, such as dry eye disease. In this webcast, Marjan Farid, MD, and Justin A. Schweitzer, OD, FAAO, present cases involving patients with early NK and discuss real-world application of diagnostic and treatment strategies that can provide the best opportunities to prevent progression in patients. The desired results of this activity are to aid clinicians in the early diagnosis and treatment of NK to prevent progression and improve patient outcomes.
Click HERE for a downloadable technician in-service tool on neurotrophic keratitis.
Target Audience
This educational activity is intended for ophthalmologists.
Learning Objectives
After completing this activity, participants will be better able to:
- Review clinical data on the treatment of patients with stage 1 NK
- Select evidence-based treatment options for patients with stage 1 NK
- Integrate evaluation of corneal sensitivity into assessment of ocular surface disease
Faculty
Marjan Farid, MD
| |
Justin A. Schweitzer, OD, FAAO
|
Disclosure Policy
MedEdicus adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been identified and mitigated by MedEdicus prior to the commencement of the activity.
Faculty
Marjan Farid, MD, is a consultant for AcuFocus, Inc, Alcon, Aldeyra Therapeutics, Allergan, Bausch & Lomb Incorporated, Bio-Tissue, CorneaGen, Dompé US, Inc, Glaukos Corporation, Johnson & Johnson Vision Care, Inc, Kala Pharmaceuticals, Novartis Pharmaceuticals Corporation, Orasis Pharmaceuticals, Oyster Point Pharma, Inc, Sun Pharmaceutical Industries, Inc, Tarsus Pharmaceuticals, Inc, and Zeiss; and is an advisory board member of AcuFocus, Inc, Alcon, Aldeyra Therapeutics, Allergan, Bausch & Lomb, Incorporated Bio-Tissue, CorneaGen, Dompé US, Inc, Glaukos Corporation, Johnson & Johnson Vision Care, Inc, Kala Pharmaceuticals, Novartis Pharmaceuticals Corporation, Orasis Pharmaceuticals, Oyster Point Pharma, Inc, Sun Pharmaceutical Industries, Inc, Tarsus Pharmaceuticals, Inc, and Zeiss.
Justin A. Schweitzer, OD, is a consultant for Aerie Pharmaceuticals, Inc, Alcon, Allergan, Avellino, Bausch & Lomb Incorporated, Dompé US, Inc, EyePoint Pharmaceuticals, Glaukos Corporation, Iveric Bio, Inc, Kala Pharmaceuticals, LKC Technologies, Inc, Novartis Pharmaceuticals Corporation, Ocular Therapeutix, Inc, Quidel Corporation, Reichert, Inc, RVL Pharmaceuticals, Inc, Sight Sciences, Sun Pharmaceutical Industries, Inc, Visus Therapeutics, and Zeiss; is an advisory board member of Aerie Pharmaceuticals, Inc, Alcon, Allergan, Avellino, Bausch & Lomb Incorporated, Dompé US, Inc, Iveric Bio, Inc, Kala Pharmaceuticals, Novartis Pharmaceuticals Corporation, Ocuphire Pharma, RVL Pharmaceuticals, Inc, ScienceBased Health, Sight Sciences, Visus Therapeutics, and Zeiss; and is on the speakers bureau for Aerie Pharmaceuticals, Inc, Alcon, Allergan, Bausch & Lomb Incorporated, Glaukos Corporation, LKC Technologies, Inc, Sight Sciences, Sun Pharmaceutical Industries, Inc, and Zeiss.
Peer Reviewer
This activity was peer reviewed. The peer reviewer has no relevant commercial relationships to disclose.
Planners, Managers, and Writers
MedEdicus planners, managers, and writers have no relevant commercial relationships to disclose.
Accreditation Statement
MedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
MedEdicus designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Commercial Support
This continuing medical education activity is supported through an educational grant from Dompé US, Inc.
Off-Label Discussion
This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.
Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at info@mededicus.com.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC or Dompé US, Inc.
©2023 MedEdicus LLC. 294.2
Available Credit
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation